Immunome Inc stock (US45254C1062): NDA submission for varegacestat in desmoid tumors

Immunome Inc announced on April 29 the submission of a New Drug Application to the FDA for varegacestat in desmoid tumors, a rare soft tissue cancer. The NASDAQ-listed biotech focuses on targeted oncology therapies.

Immunome Inc submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration on April 29 for varegacestat to treat desmoid tumors, according to Insider Monkey as of April 29, 2026. Desmoid tumors are rare, aggressive soft tissue sarcomas with limited treatment options. This filing marks a key regulatory milestone for the clinical-stage biotech.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Immunome, Inc.
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: United States
• Core markets: United States, Global
• Key revenue drivers: Pipeline drug candidates
• Home exchange/listing venue: Nasdaq (IMNM)
• Trading currency: USD

Immunome Inc: core business model

Immunome Inc develops targeted cancer therapies leveraging proprietary platforms for precision medicine. The company combines AI-driven target discovery with immunology expertise to advance oncology pipeline candidates. Its lead programs focus on gamma-secretase inhibitors and next-generation ADCs.

Headquartered in the U.S., Immunome trades on Nasdaq under ticker IMNM. The firm emphasizes therapies for solid tumors with high unmet needs, positioning it within the competitive biotech landscape relevant to U.S. investors tracking innovative oncology plays.

Main revenue and product drivers for Immunome Inc

Varegacestat, a gamma-secretase inhibitor, drives near-term value through the recent NDA submission for desmoid tumors. The molecule targets Notch signaling pathways implicated in tumor growth. Future commercialization hinges on FDA approval, potentially unlocking first-in-class status in this orphan indication.

Additional pipeline assets include IM-1617, currently in a Phase 1 trial for advanced solid tumors, per ClinicalTrials.gov as of 2026. Revenue potential stems from milestone payments, partnerships, and product sales post-approval, with U.S. market exposure via Nasdaq listing.

Industry trends and competitive position

Oncology remains a top sector for U.S. biotech investment, with precision therapies gaining traction amid rising cancer incidence. Immunome's focus on rare tumors differentiates it from broad-spectrum players, appealing to investors seeking orphan drug upside.

Conclusion

The NDA submission for varegacestat represents a pivotal step for Immunome Inc's oncology pipeline. With ongoing clinical work and U.S. market focus, the Nasdaq-listed firm continues advancing targeted therapies. Investors monitor FDA review timelines amid biotech sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.